BidaskClub downgraded shares of Aquinox Pharmaceuticals (NASDAQ:AQXP) from a hold rating to a sell rating in a report published on Tuesday.
Several other research analysts have also commented on the company. Cantor Fitzgerald reaffirmed a buy rating and set a $28.00 price target on shares of Aquinox Pharmaceuticals in a research report on Sunday, February 11th. Zacks Investment Research lowered Aquinox Pharmaceuticals from a buy rating to a hold rating in a research report on Friday, January 12th. Canaccord Genuity set a $22.00 price target on Aquinox Pharmaceuticals and gave the stock a buy rating in a research report on Tuesday, December 19th. Guggenheim started coverage on Aquinox Pharmaceuticals in a research report on Thursday, February 8th. They set a buy rating and a $26.00 price target on the stock. Finally, ValuEngine raised Aquinox Pharmaceuticals from a sell rating to a hold rating in a research report on Monday, April 2nd. Two research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company. The company has an average rating of Hold and an average price target of $22.80.
AQXP opened at $13.35 on Tuesday. Aquinox Pharmaceuticals has a 52 week low of $10.02 and a 52 week high of $16.90.
Aquinox Pharmaceuticals (NASDAQ:AQXP) last released its quarterly earnings results on Monday, March 12th. The company reported ($0.69) EPS for the quarter, missing the consensus estimate of ($0.59) by ($0.10). equities analysts anticipate that Aquinox Pharmaceuticals will post -2.27 earnings per share for the current year.
Several hedge funds have recently made changes to their positions in AQXP. D.A. Davidson & CO. grew its stake in shares of Aquinox Pharmaceuticals by 42.8% in the 4th quarter. D.A. Davidson & CO. now owns 14,350 shares of the company’s stock valued at $169,000 after purchasing an additional 4,300 shares during the last quarter. Citadel Advisors LLC purchased a new position in shares of Aquinox Pharmaceuticals in the 3rd quarter valued at approximately $194,000. Eversept Partners LLC purchased a new position in shares of Aquinox Pharmaceuticals in the 4th quarter valued at approximately $235,000. Deutsche Bank AG grew its stake in shares of Aquinox Pharmaceuticals by 157.6% in the 4th quarter. Deutsche Bank AG now owns 21,878 shares of the company’s stock valued at $257,000 after purchasing an additional 13,385 shares during the last quarter. Finally, Paloma Partners Management Co purchased a new position in shares of Aquinox Pharmaceuticals in the 4th quarter valued at approximately $304,000. Institutional investors own 91.45% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Aquinox Pharmaceuticals (AQXP) Cut to “Sell” at BidaskClub” was published by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this article on another website, it was stolen and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be accessed at https://www.dispatchtribunal.com/2018/04/13/aquinox-pharmaceuticals-aqxp-cut-to-sell-at-bidaskclub.html.
About Aquinox Pharmaceuticals
Aquinox Pharmaceuticals, Inc is a clinical-stage pharmaceutical company discovering and developing targeted therapeutics in disease areas of inflammation and immuno-oncology. The Company’s primary focus is anti-inflammatory product candidates targeting the Src Homology 2 (SH2)-containing inositol-5-phosphatase 1 (SHIP1) enzyme, which is a regulator of a cellular signaling pathway in immune cells, known as the phosphatidylinositol-4,5-bisphosphate 3-kinase (PI3K) pathway.
Receive News & Ratings for Aquinox Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aquinox Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.